ClinicalTrials.gov record
Completed Phase 4 Interventional

A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Compare Telmisartan (MICARDIS) 80 mg Versus Losartan (COZAAR) 100 mg, in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy (AMADEO Study)

ClinicalTrials.gov ID: NCT00168857

Public ClinicalTrials.gov record NCT00168857. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 11, 2026, 4:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Compare MICARDIS® (Telmisartan) 80 mg Versus COZAAR® (Losartan) 100 mg, in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy (AMADEO Study)

Study identification

NCT ID
NCT00168857
Recruitment status
Completed
Study type
Interventional
Phase
Phase 4
Lead sponsor
Boehringer Ingelheim
Industry
Enrollment
860 participants

Conditions and interventions

Interventions

  • losartan Drug
  • telmisartan Drug

Drug

Eligibility (public fields only)

Age range
21 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 8, 2003
Primary completion
May 31, 2006
Completion
Not listed
Last update posted
Dec 7, 2023

Started 2003

United States locations

U.S. sites
47
U.S. states
23
U.S. cities
44
Facility City State ZIP Site status
Boehringer Ingelheim Investigational Site Montgomery Alabama
Boehringer Ingelheim Investigational Site Little Rock Arkansas
Boehringer Ingelheim Investigational Site Lancaster California
Boehringer Ingelheim Investigational Site Los Angeles California
VA of Greater Los Angeles Los Angeles California
UCI Medical Center Orange California
VA San Diego Healthcare System San Diego California
Boehringer Ingelheim Investigational Site Santa Ana California
UCLA Medical Center Sylmar California
Torrance Clinical Research Torrance California
University of Colorado Health Sciences Center Denver Colorado
Boehringer Ingelheim Investigational Site Wheat Ridge Colorado
George Washington University Washington D.C. District of Columbia
Boehringer Ingelheim Investigational Site Hollywood Florida
Boehringer Ingelheim Investigational Site Largo Florida
Boehringer Ingelheim Investigational Site Ocala Florida
Boehringer Ingelheim Investigational Site Pembroke Pines Florida
Boehringer Ingelheim Investigational Site Tampa Florida
Boehringer Ingelheim Investigational Site Atlanta Georgia
Medical College of Georgia Augusta Georgia
Rush Presbyterian - St. Lukes Medical Center Chicago Illinois
Boehringer Ingelheim Investigational Site Des Moines Iowa
Louisiana State University Health Science Center New Orleans Louisiana
Boehringer Ingelheim Investigational Site Shreveport Louisiana
Boehringer Ingelheim Investigational Site Towson Maryland
Boehringer Ingelheim Investigational Site Boston Massachusetts
Boehringer Ingelheim Investigational Site Springfield Massachusetts
Boehringer Ingelheim Investigational Site Eatontown New Jersey
University of Medicine and Dentistry of New Jersey Newark New Jersey
Boehringer Ingelheim Investigational Site Flushing New York
Winthrop University Hospital Mineola New York
Harlem Hospital New York New York
Northport VAMC - Medical Service (111) Northport New York
Wake Nephrology Associates, PA Raleigh North Carolina
The Cleveland Foundation Cleveland Ohio
Hospital of the University of Pennsylvania Philadelphia Pennsylvania
Temple University Hospital Philadelphia Pennsylvania
VA Pittsburgh Healthcare System Pittsburgh Pennsylvania
Medical University of South Carolina Charleston South Carolina
The University of Texas Southwestern Medical Center Dallas Texas
Boehringer Ingelheim Investigational Site San Antonio Texas
University of Texas Health and Science Center at San Antonio San Antonio Texas
University of Vermont Burlington Vermont
University of Virginia Health Science Center Charlottesville Virginia
Boehringer Ingelheim Investigational Site Gig Harbor Washington
Boehringer Ingelheim Investigational Site Seattle Washington
Clement J. Zablocki Veterans Administration Medical Center Milwaukee Wisconsin

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 62 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00168857, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 7, 2023 · Synced May 11, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00168857 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →